[PARAMETERS UPDATE P5.4] EBITDA MULTIPLES
Equidam
NOVEMBER 22, 2021
The EBITDA multiples in 2021 not only reached, but much exceeded pre-pandemic levels. It is too early to determine the reasons why the EBITDA multiple for footwear companies surpasses 33X, while the multiple for MedTech firms exceeds 35X. On the one hand, the market’s excess liquidity might be a factor. 9,05. ? -5%.
Let's personalize your content